Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2010

View Archived Issues

Banyu and Merck & Co. claim novel Akt1 inhibitors for cancer therapy

Everolimus effective in patients with metastatic pancreatic neuroendocrine tumors

Synta Pharmaceuticals discloses Hsp90 inhibitors for the treatment of cancer

TRPA1 antagonists described by Janssen for the treatment of pain

Roche describes liver X receptor agonists for the treatment of atherosclerosis

Novartis claims ENaC blockers for the treatment of cystic fibrosis

Oramed completes patient enrollment in pivotal phase IIb trial of ORMD-0801

Orexin receptor antagonists for treating sleep disorders claimed by Actelion

Cobalamin oral insulin shows promise in preclinical trials

Michael J. Fox Foundation awards grant for neuroprotective therapies for PD

Halozyme Therapeutics enters research alliance with BioAtla

Novel hybrid potentiator-corrector molecule for the treatment of CF disclosed

Generation of tumor-targeted nanoparticles for potential clinical use

Sorafenib shows low activity in phase II trial in advanced biliary tract carcinoma

Dal-OUTCOMES trial to evaluate dalcetrapib in acute coronary syndrome

NS3/4A protease inhibitors reported by BMS for HCV infection

Shionogi's Cymbalta approved for depression in Japan

Schering-Plough obtains Japanese approval for Bridion

Wyeth launches BeneFIX for hemophilia B

ImmunoCellular's ICT-107 vaccine specifically targets cancer stem cells

Bharat Biotech initiates phase I clinical trial of HN-VAC H1N1 vaccine

Lexicon's LX-4211 demonstrates improvements in phase II trial in type 2 diabetes

New dosage form of Mitsubishi Tanabe's neuroprotectant Radicut approved

BTG initiates phase IIa study of Pleneva in multiple sclerosis

4SC commences dosing in a first-in-man phase I study of 4SC-203

Mitsubishi Tanabe's Remicade approved for the additional indication of psoriasis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...